Item 2.02. Results of Operations and Financial Condition

On January 8, 2023, Alnylam Pharmaceuticals, Inc. (the "Company") announced its preliminary fourth quarter and full year 2022 global net product revenues of approximately $262 million and $894 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran), and provided additional updates on the products' commercial launches. The Company also updated its cash guidance for the year ended December 31, 2022, stating that at December 31, 2022, it had preliminary cash, cash equivalents and marketable securities of approximately $2.2 billion.

The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2023.

The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:



99.1      Press Release dated January 8, 2023.

104     Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses